跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
Iron therapy in chronic kidney disease: Days of future past
Kuo Hua Lee, Yang Ho, Der Cherng Tarng
*
*
此作品的通信作者
生理學科暨研究所
研究成果
:
Review article
›
同行評審
13
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Iron therapy in chronic kidney disease: Days of future past」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Futures Past
100%
Chronic Kidney Disease
100%
Iron Therapy
100%
Infusion Reaction
66%
Ferric Pyrophosphate Citrate
66%
High Dose
33%
Iron Loss
33%
Risk Reduction
33%
Potential Risk
33%
Transferrin
33%
Hemodialysis
33%
Hemoglobin Level
33%
Recent Advancements
33%
Renal Anemia
33%
Anemia
33%
Gastrointestinal
33%
Medical Costs
33%
Maintenance Hemodialysis Patients
33%
Dialysate
33%
Iron Supplementation
33%
Erythropoiesis-stimulating Agents
33%
1,25-dihydroxyvitamin D3
33%
Ferric Citrate
33%
Phosphate Binder
33%
Anemia Management
33%
Intravenous Iron
33%
Iron Stores
33%
Intolerability
33%
Iron Preparations
33%
Iron Sequestration
33%
Ferric Carboxymaltose
33%
Iron Isomaltoside
33%
Fibroblast Growth Factor 23 (FGF23)
33%
Citrate Transport
33%
Iron Replacement Therapy
33%
Hypoxia-inducible Factor Prolyl Hydroxylase
33%
Ferumoxytol
33%
Treatment of Iron Deficiency Anemia
33%
Medicine and Dentistry
Infusion
100%
Chronic Kidney Disease
100%
Iron Supplement
100%
Iron
100%
Anemia
66%
Hemodialysis
66%
Ferric Pyrophosphate
66%
Health Care Cost
33%
Transferrin
33%
Drug Megadose
33%
Supplementation
33%
Reticuloendothelial System
33%
Dialysis Fluid
33%
Hematinic
33%
Phosphate Binder
33%
Ferric Citrate
33%
Iron Storage
33%
Hypoxia Inducible Factor Proline Dioxygenase
33%
Fibroblast Growth Factor 23
33%
Substitution Therapy
33%
Ferumoxytol
33%
Hypochromic Anemia
33%
Iron Transport
33%
Ferric Carboxymaltose
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Iron
100%
Hemodialysis
66%
Anemia
66%
Ferric Pyrophosphate
66%
Transferrin
33%
Dialysis Fluid
33%
Replacement Therapy
33%
Antianemic Agent
33%
Phosphate Binding Agent
33%
Ferric Citrate
33%
Fibroblast Growth Factor 23
33%
Iron Deficiency Anemia
33%
Ferric Carboxymaltose
33%
Ferumoxytol
33%
Hypoxia Inducible Factor Proline Dioxygenase
33%